Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
3.150
-0.230 (-6.80%)
Mar 31, 2025, 3:50 PM EDT - Market open

Eupraxia Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2017
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2017
Selling, General & Admin
10.927.483.998.21.27
Upgrade
Research & Development
16.0820.3613.639.590.86
Upgrade
Operating Expenses
2727.8517.6217.912.25
Upgrade
Operating Income
-27-27.85-17.62-17.91-2.25
Upgrade
Interest Expense
-0.96-1.17-0.98-1.23-1.88
Upgrade
Interest & Investment Income
1.160.860.430.070
Upgrade
Currency Exchange Gain (Loss)
-0.160.070.240.20.13
Upgrade
Other Non Operating Income (Expenses)
1.2-0.84-1.06-60.12
Upgrade
EBT Excluding Unusual Items
-25.76-28.92-18.98-24.87-3.88
Upgrade
Gain (Loss) on Sale of Assets
0.02-0-0.01--0.13
Upgrade
Other Unusual Items
---0.53-
Upgrade
Pretax Income
-25.74-28.93-18.99-24.34-4.01
Upgrade
Income Tax Expense
00.04---
Upgrade
Earnings From Continuing Operations
-25.74-28.97-18.99-24.34-4.01
Upgrade
Minority Interest in Earnings
0.240.750.50.380.01
Upgrade
Net Income
-25.5-28.22-18.49-23.96-4
Upgrade
Preferred Dividends & Other Adjustments
0.43----
Upgrade
Net Income to Common
-25.93-28.22-18.49-23.96-4
Upgrade
Shares Outstanding (Basic)
342419126
Upgrade
Shares Outstanding (Diluted)
342419126
Upgrade
Shares Change (YoY)
40.52%25.21%55.45%102.75%0.01%
Upgrade
EPS (Basic)
-0.76-1.17-0.96-1.93-0.65
Upgrade
EPS (Diluted)
-0.76-1.17-0.96-1.93-0.65
Upgrade
Free Cash Flow
-30.1-20.82-14.63-15.26-0.4
Upgrade
Free Cash Flow Per Share
-0.89-0.86-0.76-1.23-0.07
Upgrade
EBITDA
-26.89-27.73-17.51-17.85-2.2
Upgrade
D&A For EBITDA
0.110.110.110.060.04
Upgrade
EBIT
-27-27.85-17.62-17.91-2.25
Upgrade
Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q